Paulex Bio

Funding and NIH signals

• SEC Form D raise Raised $18.52M (Form D filed Dec 18, 2025). SEC Form D 0001493152-25-028344 (Dec 18, 2025)
  Evidence (1 event)

  • Dec 18, 2025 · SEC Form D 0001493152-25-028344
    Name of Issuer: Paulex Bio Inc.; CIK: 2071082; Address: LA Jolla, CA; Submission type: D; Filing date: 2025-12-18; Industry Group: Pharmaceuticals; Date of First Sale: 2025-11-21; Types of Securities Offered: Equity, Option/warrant; Business combination transaction: false; Total Offering Amount: 22500000; Total Amount Sold: 18516040; Federal exemptions: 06c
• NIH award NIH awarded $350K (STTR Phase II 1R42DK148220-01, new, notice Sep 10, 2026). NIH RePORTER 1R42DK148220-01 (Sep 10, 2026)
  Evidence (1 event)

  • Sep 10, 2026 · NIH RePORTER 1R42DK148220-01
    Organization: PAULEX BIO INC.; City/State: LA JOLLA, CA; Project number: 1R42DK148220-01; Activity code: R42; Fiscal year: 2026; Award notice date: 2026-09-10; FY total cost (award amount): 350000; Administering IC: National Institute of Diabetes and Digestive and Kidney Diseases; Project title: Preclinical Development of Paulex-4 for Human Trials for Beta Cell Regeneration to treat Diabetes; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals